{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:02:14Z","timestamp":1789826534407,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003661","name":"Korea Institute for Advancement of Technology","doi-asserted-by":"publisher","award":["P0022105"],"award-info":[{"award-number":["P0022105"]}],"id":[{"id":"10.13039\/501100003661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003715","name":"Korea Research Institute of Bioscience & Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["2021R1I1A3056261"],"award-info":[{"award-number":["2021R1I1A3056261"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.heliyon.2024.e38637","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:20:19Z","timestamp":1727536819000},"page":"e38637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quality by design-based approach for the development of an analytical method for quantifying ponatinib in rat plasma"],"prefix":"10.1016","volume":"10","author":[{"given":"Nahyun","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong-Ryoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-4192","authenticated-orcid":false,"given":"Yoon-Jee","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e38637_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial","volume":"27","author":"Pulte","year":"2022","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e38637_bib2","first-page":"371","article-title":"Management of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"2009","author":"Ottmann","year":"2009","journal-title":"ASH Educ. Progr. B."},{"key":"10.1016\/j.heliyon.2024.e38637_bib3","series-title":"Harrisons Principles of Internal Medicine","author":"Longo","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e38637_bib4","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","article-title":"Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including t","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.heliyon.2024.e38637_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.V124.21.519.519","article-title":"Epic: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML)","volume":"124","author":"Lipton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e38637_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110430","article-title":"Recent studies on ponatinib in cancers other than chronic myeloid leukemia","volume":"10","author":"Musumeci","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e38637_bib7","doi-asserted-by":"crossref","first-page":"E811","DOI":"10.1210\/jc.2012-2672","article-title":"Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer","volume":"98","author":"De Falco","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.heliyon.2024.e38637_bib8","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","article-title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients","volume":"20","author":"Garner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e38637_bib9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbrc.2015.06.029","article-title":"Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity","volume":"463","author":"Ahmad","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2024.e38637_bib10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2016.10.005","article-title":"Dual targeting of PDGFR\u03b1 and FGFR1 displays synergistic efficacy in malignant rhabdoid tumors","volume":"17","author":"Wong","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e38637_bib11","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3892\/or.2013.2386","article-title":"Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1","volume":"29","author":"Ren","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e38637_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-17-0841","article-title":"A high-content screening of anticancer compounds suggests the multiple tyrosine kinase inhibitor ponatinib for repurposing in neuroblastoma therapy","volume":"17","author":"Sidarovich","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.heliyon.2024.e38637_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00216-012-6302-2","article-title":"Application of quality by design to the development of analytical separation methods","volume":"405","author":"Orlandini","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.heliyon.2024.e38637_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s43094-023-00546-5","article-title":"Method operable design region for robust RP-HPLC analysis of pioglitazone hydrochloride and teneligliptin hydrobromide hydrate: incorporating hybrid principles of white analytical chemistry and design of experiments","volume":"9","author":"Prajapati","year":"2023","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.heliyon.2024.e38637_bib15","article-title":"Robust method operable design region for economical and eco-friendly chromatographic analysis of azilsartan medoxomil and cilnidipine by incorporating a hybrid approach of green analytical chemistry and analytical quality by design, Sep","volume":"6","author":"Prajapati","year":"2023","journal-title":"Sci. PLUS."},{"key":"10.1016\/j.heliyon.2024.e38637_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s42250-023-00819-9","article-title":"Integrated approach of white analytical chemistry and analytical quality by design to multipurpose RP-HPLC method for synchronous estimation of multiple fixed-dose combinations of paracetamol","volume":"7","author":"Prajapati","year":"2024","journal-title":"Chem. Africa"},{"key":"10.1016\/j.heliyon.2024.e38637_bib17","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s42250-023-00835-9","article-title":"Multipurpose RP-HPLC method for simultaneous estimation of fixed-dose combinations of anti-diabetic drugs: integrating green, economical, and robust approaches with design of experiments and white analytical chemistry","volume":"7","author":"Prajapati","year":"2024","journal-title":"Chem. Africa"},{"key":"10.1016\/j.heliyon.2024.e38637_bib18","article-title":"Analytical quality by design (AQbD) in the ICHQ14 guidelines for analytical procedure development","author":"Sathuluri","year":"2024","journal-title":"Accredit. Qual. Assur."},{"key":"10.1016\/j.heliyon.2024.e38637_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164967","article-title":"Validated LC-MS\/MS method for the quantification of ponatinib in plasma: application to metabolic stability","volume":"11","author":"Kadi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e38637_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40487-016-0022-2","article-title":"Liquid chromatography-mass spectrometry\/mass spectrometry analysis and pharmacokinetic assessment of ponatinib in sprague-dawley rats","volume":"4","author":"Wang","year":"2016","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.heliyon.2024.e38637_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s40543-020-00219-5","article-title":"Development and validation of an LC-MS\/MS method for monitoring larotrectinib, a tropomyosin-related kinase inhibitor, in mouse and human plasma and application to pharmacokinetic studies","volume":"11","author":"Chae","year":"2020","journal-title":"J. Anal. Sci. Technol."},{"key":"10.1016\/j.heliyon.2024.e38637_bib24","first-page":"1347","article-title":"Sensitive and valid assay for reliable evaluation of drug interactions mediated by human organic anion transporter 1 and 3 using 5-carboxyfluorescein","volume":"38","author":"Lee","year":"2022","journal-title":"Anal. Sci. Int. J. Japan Soc. Anal. Chem."},{"key":"10.1016\/j.heliyon.2024.e38637_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40543-022-00340-7","article-title":"Bioanalysis of alpelisib using liquid chromatography\u2013tandem mass spectrometry and application to pharmacokinetic study","volume":"13","author":"Lee","year":"2022","journal-title":"J. Anal. Sci. Technol."},{"key":"10.1016\/j.heliyon.2024.e38637_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1248\/bpb.b17-00806","article-title":"Simple determination of plasma ponatinib concentration using HPLC","volume":"41","author":"Yasu","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.heliyon.2024.e38637_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2017.11.012","article-title":"Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients","volume":"64","author":"Abumiya","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.heliyon.2024.e38637_bib28","unstructured":"Ponatinib, Clinical Pharmacology and Biopharmaceutics Review, United States Food and Drug Administration, (n.d.). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469Orig1s000ClinPharmR.pdf (accessed September 5, 2024)."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024146683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024146683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:04:03Z","timestamp":1789823043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024146683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2405844024146683"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38637","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality by design-based approach for the development of an analytical method for quantifying ponatinib in rat plasma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e38637"}}